• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » STAAR lands new FDA panel date, Japanese approval for implantable lenses

STAAR lands new FDA panel date, Japanese approval for implantable lenses

March 4, 2014 By Arezu Sarvestani

STAAR lands FDA panel date, Japanese approval for implantable lenses

California ophthalmic devices maker STAAR Surgical (NSDQ:STAA) touted a pair of regulatory wins, landing a date with an FDA advisory panel and notching new Japanese market approval for its Visian Implantable Collamer Lens with CentraFLOW technology.

STAAR will meet next week with the FDA’s Ophthalmic Devices Panel to review the premarket approval application for the company’s Visian Toric ICL for treatment of myopic astigmatism. The original meeting, scheduled for February 14, was postponed over weather concerns.

Next week’s panel will discuss safety and efficacy data on the Visian Toric ICL, addressing FDA concerns about a series of deviations from the protocol for the study used to back the PMA bid.

The agency issued a warning letter in April 2004 after an inspection of a plant in Monrovia in December 2003 cited STAAR for "failure to obtain FDA approval prior to initiating a study, failure to ensure continuing Institutional Review Board (IRB) review and approval, failure to obtain signed Investigator Agreements from participating investigators, and failure to provide participating Clinical Investigators with all the information required to perform the study," according to the pre-meeting materials.

Survey: Will the FDA panel OK STAAR Surgical’s Toric ICL lens?

The FDA wants the advisory panel to consider whether there’s enough data to asses the safety and effectiveness of the Toric ICL implant. The FDA isn’t bound by the recommendations made by its advisory panels, but often follows their lead in its final decisions.


STAAR further notched Japanese regulatory approval for a new version of its Visian implant featuring CentraFLOW technology, which the company called a "key driver to our growth of Visian ICL revenues the past several quarters."

CentraFLOW allows physicians to treat a larger range of patients with the Visian ICL, expanding to myopia starting at -3.0 diopters, up from the current range at -5.0 diopters, according to a press release.

STAA shares closed last night at $14.30, up 1% on the day.

Filed Under: Implants, News Well, Optical/Ophthalmic, Pre-Market Approval (PMA) Tagged With: STAAR Surgical Co

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy